Search Videos and More
News
Dana-Farber Research News 12.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 1 - 15.
Symposium
San Antonio Breast Cancer Symposium 2025
Dana-Farber Cancer Institute Faculty highlights from the 2025 San Antonio Breast Cancer Symposium.
Video
ESMO25 Breast Cancer Highlights: ASCENT-03 and TROPION-Breast02
Harold Burstein, MD, PhD, and Ana Garrido- Castro, MD, discuss the ASCENT-03 and TROPION-Breast02 trials, investigating antibody-drug conjugates for triple-negative breast cancer.
Video
ESMO25 Breast Cancer Highlights: DESTINY-Breast11 & DESTINY-Breast05
Harold Burstein, MD, PhD, and Guilherme Nader Marta, MD, discuss the DESTINY-Breast11 and DESTINY-Breast05 trials examining trastuzumab deruxtecan in HER2-positive breast cancer.
Video
ESMO25 Breast Cancer Highlights: monarchE and NATALEE
Harold Burstein, MD, PhD, and Sarah Sammons, MD, discuss the monarchE and NATALEE trials, investigating CDK4/6 inhibitors for high-risk, early stage, HR+ breast cancer.
Video
ESMO25 Breast Cancer Highlights: evERA and SERENA6
Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH, discuss the evERA and SERENA6 trials investigating oral selective estrogen receptor degraders (SERDs).
Video
ESMO25 Breast Cancer Highlights: Antibody-Drug Conjugates
Harold Burstein, MD, PhD, and Ilana Schlam, MD, MPH, discuss OptiTROP-Breast02 and other trials investigating antibody-drug conjugates (ADCs).
Video
ESMO25 Breast Cancer Highlight Recap
Harold Burstein, MD, PhD, summarizes important breakthroughs presented at ESMO 2025 for all sub-types and stages of breast cancer.
Video
ESMO25 Breast Cancer Highlights
Harold Burstein, MD, PhD, and other breast cancer experts at Dana-Farber discuss important breast cancer research presented at ESMO 2025.
News
Dana-Farber Research Opens the Door to Finding More Effective Treatments for Ewing Sarcoma
In 2014, Dana-Farber pediatric oncologist Brian Crompton, MD, discovered that a gene called STAG2 is mutated in about 15 percent of patients with Ewing sarcoma, a form of bone cancer that largely occurs in children and adolescents.
News
Dana-Farber Research Supports FDA Approval of Sevabertinib for HER2-Mutant Lung Cancer
The US Food and Drug Administration has approved sevabertinib, an oral targeted therapy for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (also called ERBB2) mutations and who have previously received chemotherapy or immunotherapy.
Video
2025 ESMO Prostate Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ESMO 2025